Modern medicine now offers powerful tools such as Tirzepatide (Mounjaro) and Semaglutide (Ozempic/Wegovy).

However, success is not measured only in pounds or kilograms. At the Endocrine and Dermatology Clinic in Thessaloniki, our approach is holistic: we combine Endocrine safety with Dermatological excellence to ensure you lose weight while preserving your facial aesthetics and hair health.

1. Endocrinologist Evangelia Yazitzoglou: Prescription and Monitoring for Results and Safety

Prescribing Ozempic or Mounjaro requires precise medical supervision.

• What we do: We adjust the dosage to minimize side effects and monitor your hormonal balance to ensure your weight loss journey is 100% safe.

• Why choose our Endocrine clinic in Thessaloniki: We provide direct, in-person monitoring at our clinic for every stage of your treatment.

2. Dermatologist Konstantinos Stamatopoulos: Addressing “Ozempic Face” & “Mounjaro Hair” (Hair Loss)

Rapid weight loss has two major aesthetic enemies: skin sagging and hair thinning.

• Face Contouring: We utilize Fillers, Skin Boosters, or Threads to prevent the “tired face” look caused by sudden fat loss in the facial area.

• Hair Loss (Telogen Effluvium): Rapid weight reduction can shock hair follicles. We apply Mesotherapy, PRP, and specialized strengthening protocols to ensure your hair remains thick and healthy.

3. Clinical Nutritionist: Preserving Muscle Mass

The goal is to lose fat, not muscle. We design your nutrition plan with high protein and essential micronutrients, specifically tailored for GLP-1 medication users.

• Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). The New England Journal of Medicine.

  This study serves as the data foundation for Mounjaro, demonstrating an average weight loss of up to 20.9% over a 72-week period. Read the study here

• Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). The New England Journal of Medicine.

  The fundamental study for Ozempic/Wegovy (Semaglutide), documenting an average weight loss of 14.9% in participants. Read the study here

• Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine.

  A study examining the long-term maintenance of weight loss and the safety of the medication over a two-year period. Read the study here

• Malkud, S. (2015). Telogen Effluvium: A Review. Journal of Clinical and Diagnostic Research.

  Medical reference linking rapid weight loss with the onset of Telogen Effluvium (Hair Loss). Read the study here